Abstract
Unfortunately, antiepileptic drug therapy fails to control seizure activity in a relevant percentage of epilepsy patients. Epidemiological data as well as findings in human epileptic tissue and in rodent models indicate that drug resistance is a multi-factorial phenomenon with various factors contributing to therapeutic failure. Enhanced efflux transport of antiepileptic drugs as a consequence of seizure-associated up-regulation of transporters such as P-glycoprotein constitutes one factor discussed in this context. Evidence exists that expression rates of P-glycoprotein correlate with drug response in rodent models and in patients. Moreover, add-on of a Pglycoprotein modulator proved to be efficacious in a rat model of drug-resistant epilepsy.
Further proof is obviously needed regarding the relative functional relevance of blood-brain barrier efflux for antiepileptic drug efficacy in epilepsy patients. Ongoing studies with positron emission tomography using transporter substrate radiotracers might provide further information. However, these studies also face major challenges considering the complexity of various factors affecting the kinetics of radiotracers in central nervous system pathologies.
Keywords: Seizure, blood-brain barrier, transporter, drug resistance, p-glycoprotein.
Current Pharmaceutical Design
Title:CNS Transporters and Drug Delivery in Epilepsy
Volume: 20 Issue: 10
Author(s): Heidrun Potschka and Hiram Luna-Munguia
Affiliation:
Keywords: Seizure, blood-brain barrier, transporter, drug resistance, p-glycoprotein.
Abstract: Unfortunately, antiepileptic drug therapy fails to control seizure activity in a relevant percentage of epilepsy patients. Epidemiological data as well as findings in human epileptic tissue and in rodent models indicate that drug resistance is a multi-factorial phenomenon with various factors contributing to therapeutic failure. Enhanced efflux transport of antiepileptic drugs as a consequence of seizure-associated up-regulation of transporters such as P-glycoprotein constitutes one factor discussed in this context. Evidence exists that expression rates of P-glycoprotein correlate with drug response in rodent models and in patients. Moreover, add-on of a Pglycoprotein modulator proved to be efficacious in a rat model of drug-resistant epilepsy.
Further proof is obviously needed regarding the relative functional relevance of blood-brain barrier efflux for antiepileptic drug efficacy in epilepsy patients. Ongoing studies with positron emission tomography using transporter substrate radiotracers might provide further information. However, these studies also face major challenges considering the complexity of various factors affecting the kinetics of radiotracers in central nervous system pathologies.
Export Options
About this article
Cite this article as:
Potschka Heidrun and Luna-Munguia Hiram, CNS Transporters and Drug Delivery in Epilepsy, Current Pharmaceutical Design 2014; 20 (10) . https://dx.doi.org/10.2174/13816128113199990461
DOI https://dx.doi.org/10.2174/13816128113199990461 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Journey Describing the Cytotoxic Potential of Withanolides: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Nerolidol and its Pharmacological Application in Treating Neurodegenerative Diseases: A Review
Recent Patents on Biotechnology Seizures and Sodium Hydrogen Exchangers: Potential of Sodium Hydrogen Exchanger Inhibitors as Novel Anticonvulsants
CNS & Neurological Disorders - Drug Targets Integration of <sup>18</sup>FDG-PET Metabolic and Functional Connectomes in the Early Diagnosis and Prognosis of the Alzheimer's Disease
Current Alzheimer Research Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Knowledge of Pharmacists about Anti-epileptic Drugs in a Developing Country
Current Drug Safety Exogenous Progesterone: A Potential Therapeutic Candidate in CNS Injury and Neurodegeneration
Current Medicinal Chemistry Cofactors and Metabolites as Protein Folding Helpers in Metabolic Diseases
Current Topics in Medicinal Chemistry Erythropoietin: A Neuroprotective Agent in Cerebral Hypoxia, Neurodegeneration, and Epilepsy
Current Pharmaceutical Design The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment
CNS & Neurological Disorders - Drug Targets Synthesis and Evaluation of the Anticonvulsant Activities of New 5-substitued-[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one Derivatives
Letters in Drug Design & Discovery Editorial (Thematic Issue: Current Status and Progress of Radiopharmaceuticals for Molecular Imaging and Targeted Therapy)
Current Medicinal Chemistry A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects
Current Drug Abuse Reviews Phytochemical Screening, In vivo Anthelmintic and Anticonvulsant Activity of Cleome viscosa Linn Seeds Extract
The Natural Products Journal Recent Advances in MRI Based Volumetry and Morphometry for AD Diagnosis in Human
Current Medical Imaging